TrovaGene Inc  

(Public, NASDAQ:TROVU)   Watch this stock  
Find more results for TROVU
+1.02 (6.89%)
Real-time:   12:29PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.02 - 17.00
Open     -
Vol / Avg. 0.00/87.00
Mkt cap 147.52M
P/E     -
Div/yield     -
EPS -0.57
Shares 1.67M
Beta     -
Inst. own 225%
Mar 12, 2015
Q4 2014 Trovagene Inc Earnings Call - 5:00PM EDT - Add to calendar
Mar 12, 2015
Q4 2014 Trovagene Inc Earnings Release - 4:00PM EDT - Add to calendar
Feb 12, 2015
Trovagene Inc at Leerink Global Healthcare Conference
Jan 12, 2015
Trovagene Inc at EBD Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9397.24% -4555.81%
Operating margin -6888.51% -4123.64%
EBITD margin - -4073.30%
Return on average assets -62.53% -60.85%
Return on average equity -145.43% -104.97%
Employees 21 -
CDP Score - -


United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Trovagene, Inc. (TrovaGene) is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Company�s internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology and external focus includes entering into collaborations to develop the Company�s technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Company�s San Diego-based CLIA-certified laboratory uses diagnostic technology for cancer mutation assays. Trovagene offers physicians control by tracking patient response to therapy with the choice of blood- or urine-based molecular tests that measures cancer-related gene mutations.

Officers and directors

Thomas H. Adams Jr., Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Antonius P. Schuh Ph.D. Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Stephen L. Zaniboni Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Mark Erlander Chief Scientific Officer
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq Director
Age: 70
Bio & Compensation  - Reuters
Paul R. Billings M.D., Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 66
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters